Source:Journal of Allergy and Clinical Immunology
Author(s): Helen Cao, Mark Biondo, Hadi Lioe, Samantha Busfield, Veronika Rayzman, Bernhard Nieswandt, Konrad Bork, Leonard C. Harrison, Priscilla Auyeung, Henriette Farkas, Dorottya Csuka, Matthias Pelzing, Steve Dower, Michael J. Wilson, Andrew Nash, Marc W. Nolte, Con Panousis
Teaser
HAE results in swelling due to KKS dysregulation and bradykinin production. FXII initiates the KKS and we have developed a human antibody that potently inhibits FXII protease activity as a novel prophylactic therapy for HAE.https://ift.tt/2Kf2Pwh
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου